Lymphoplasmacytic lymphoma (LPL) is a rare type of cancer. We’ll tell you the symptoms, causes, treatment options, and what to look out for.

Lymphoplasmacytic lymphoma involving the bone marrow can be difficult to diagnose, and pathological features that predict the presence of associated Waldenström's macroglobulinemia have yet to be ...

Emerging data suggest a role for genetic and immune-related factors in lymphoplasmacytic lymphoma/WM. This article reviews recently published, population-based studies substantiating this assertion.

The current approach to lymphoplasmacytic lymphoma care is active surveillance of a patient's possible symptoms. There is a median time of 3.5 years from diagnosis to progression of symptoms ...

The current approach to lymphoplasmacytic lymphoma care is active surveillance of a patient's possible symptoms. There is a median time of 3.5 years from diagnosis to progression of symptoms ...

Approximately one-third of patients with Waldenström macroglobulinemia (WM), a subset of lymphoplasmacytic lymphoma (LPL), had malignancies and all other patients had increased mast cells (MC ...

--Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the ...

The lack of characteristic histopathology is most pronounced in lymph nodes, lymphoma-like presentations in the orbit, and certain kidney manifestations, such as tubulointerstitial nephritis.

The current approach to lymphoplasmacytic lymphoma care is active surveillance of a patient's possible symptoms. There is a median time of 3.5 years from diagnosis to progression of symptoms ...

The research reported in the Nature Communications paper, “Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 ...

City of Hope vaccine experts have reported positive results from a Phase 1 trial of a personalized vaccine for lymphoplasmacytic lymphoma. Data demonstrates the safety and efficacy of this early ...